We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lamivudine and Adefovir to Treat Chronic Hepatitis B

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00023309
First Posted: September 3, 2001
Last Update Posted: September 23, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Marc Ghany, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Results First Submitted: July 7, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: HBV (Hepatitis B Virus)
Hepatitis B
Hepatitis
Interventions: Drug: Lamivudine and adefovir
Drug: Adefovir alone

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Lamivudine and Adefovir Patients to receive combination lamivudine and adefovir
Adefovir Patients to receive adefovir alone
Total Total of all reporting groups

Baseline Measures
   Lamivudine and Adefovir   Adefovir   Total 
Overall Participants Analyzed 
[Units: Participants]
 22   19   41 
Age 
[Units: Years]
Mean (Standard Deviation)
 46  (14)   45  (13)   45  (14) 
Gender 
[Units: Participants]
     
Female   6   1   7 
Male   16   18   34 
Race/Ethnicity, Customized 
[Units: Participants]
     
White   9   8   17 
Asian   9   10   19 
Black   4   1   5 
Region of Enrollment 
[Units: Participants]
     
United States   22   19   41 
Treatment Naive 
[Units: Participants]
     
Yes   17   14   31 
No   5   5   10 
HBeAg positive 
[Units: Participants]
     
Yes   17   14   31 
No   5   5   10 
ALT [1] 
[Units: IU/ml]
Mean (Standard Deviation)
 183  (250)   87  (56)   139  (187) 
[1] Alanine transaminase
HBV DNA Log 10 copies per ml [1] 
[Units: Log10(copies/ml)]
Mean (Standard Deviation)
 8.1  (1.3)   7.8  (1.6)   8.0  (1.4) 
[1] Hepatitis B virus DNA logarithm 10 copies per ml
HAI [1] 
[Units: Units on a scale]
Mean (Standard Deviation)
 8.1  (2.7)   7.9  (2.4)   8.0  (2.6) 
[1] HAI Fibrosis score for liver histology, which has a range 0–18 and higher values represent a worse outcome
Ishak [1] 
[Units: Units on a scale]
Mean (Standard Deviation)
 3.3  (1.7)   2.4  (1.5)   2.9  (1.6) 
[1] Ishak Fibrosis Score, (range 0–6, where 0 = no fibrosis and 6 = cirrhosis)
Cirrhosis 
[Units: Participants]
     
Yes   5   2   7 
No   17   17   34 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Maintained Combined Response (Virological, Biochemical and Histological Response).   [ Time Frame: 196 weeks from randomization ]

2.  Secondary:   HBeAg Loss at Week 196   [ Time Frame: Week 196 from randomization ]

3.  Secondary:   Virological Response   [ Time Frame: Week 196 from randomization ]

4.  Secondary:   Biological Response   [ Time Frame: week 196 from randomization ]

5.  Secondary:   Histological Response   [ Time Frame: week 196 from randomization ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information